{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:35:56Z","timestamp":1785537356019,"version":"3.56.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To assess disease activity, steroid-free remission, and other clinical outcome assessments among pediatric patients with ulcerative colitis (UC) and Crohn\u2019s disease (CD) in the ImproveCareNow (ICN) registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged 2\u201317 years diagnosed with UC or CD between June 1, 2013 and December 31, 2019 were enrolled if they initiated a biologic after enrollment in the ICN registry and completed at least 12 months follow-up after first maintenance dose. Baseline (at biologic initiation) demographics were summarized using descriptive statistics. Pediatric UC Activity Index (PUCAI), partial Mayo score, and Physician Global Assessment (PGA) were assessed for UC; and the Short Pediatric Crohn\u2019s Disease Activity Index (sPCDAI) and PGA were assessed for CD at first maintenance dose, 1- and 3-year time points. Kappa coefficients were used to assess the level of agreement between the outcome measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1887 patients (UC = 350; CD = 1537) were included. Baseline demographics were similar across groups. For UC patients, mean PUCAI scores decreased and the proportion of patients in steroid-free remission, quiescent state based on PGA, and remission based on partial Mayo score increased from first maintenance dose to 1 and 3 years. For CD patients, mean sPCDAI score of CD patients decreased and the proportion of patients in steroid-free remission by sPCDAI and in quiescent state based on PGA increased from first maintenance dose to 1 and 3 years. Kappa coefficients showed only modest correlation between disease activity assessments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Disease activity scores improved over time, with more pediatric patients with UC and CD achieving steroid-free remission at 1 and 3 years after first biologic maintenance dose.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otac009","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:38:45Z","timestamp":1647549525000},"source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn\u2019s Disease Receiving Biologics: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa","family":"Hunter","sequence":"first","affiliation":[{"name":"Value Evidence and Outcomes, Eli Lilly and Company , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J","family":"Komocsar","sequence":"additional","affiliation":[{"name":"Department of Immunology, Eli Lilly and Company , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Epidemiology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Colletti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Vermont College of Medicine , Burlington, Vermont , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Indiana University School of Medicine , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Dotson","sequence":"additional","affiliation":[{"name":"Center for Pediatric and Adolescent Inflammatory Bowel Disease, Nationwide Children\u2019s Hospital , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Benkov","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Icahn School of Medicine at Mount Sinai , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio , USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Crandall","sequence":"additional","affiliation":[{"name":"Department of Immunology, Eli Lilly and Company , Indianapolis, Indiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"issue":"4","key":"2022111812243617400_CIT0001","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"11","key":"2022111812243617400_CIT0002","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents.","volume":"169","author":"Rosen","year":"2015","journal-title":"JAMA Pediatr."},{"issue":"1","key":"2022111812243617400_CIT0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"4","key":"2022111812243617400_CIT0004","first-page":"619","article-title":"Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from Large National Databases in the United States, 2007\u20132016.","volume":"26","author":"Ye","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2022111812243617400_CIT0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ibd\/izy207","article-title":"Challenges in transitional care in inflammatory bowel disease: a review of the current literature in transition readiness and outcomes.","volume":"25","author":"Philpott","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2022111812243617400_CIT0006","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ibd.21152","article-title":"Natural history of Crohn\u2019s disease: comparison between childhood- and adult-onset disease.","volume":"16","author":"Pigneur","year":"2010","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2022111812243617400_CIT0007","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology."},{"issue":"12","key":"2022111812243617400_CIT0008","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.mib.0000235835.32176.85","article-title":"A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn\u2019s disease and ulcerative colitis.","volume":"12","author":"Tung","year":"2006","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2022111812243617400_CIT0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00005176-200302000-00017","article-title":"A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease.","volume":"36","author":"Levine","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"5","key":"2022111812243617400_CIT0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology."},{"issue":"2","key":"2022111812243617400_CIT0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrgastro.2009.222","article-title":"Top-down therapy for IBD: rationale and requisite evidence.","volume":"7","author":"D\u2019Haens","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"8","key":"2022111812243617400_CIT0012","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jgh.14648","article-title":"Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn\u2019s disease in Asia.","volume":"34","author":"Ooi","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"issue":"13","key":"2022111812243617400_CIT0013","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1097\/MIB.0b013e31829aad16","article-title":"Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease.","volume":"19","author":"Dulai","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"supplement","key":"2022111812243617400_CIT0014","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.14309\/00000434-201810001-00726","article-title":"Sustained steroid free remission at one year in corticosteroid dependent ulcerative colitis patients on vedolizumab: 726.","volume":"113","author":"Bollu","year":"2018","journal-title":"J Am Coll Gastroenterol."},{"issue":"2","key":"2022111812243617400_CIT0015","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/MPG.0000000000002557","article-title":"A new video aid for communicating risk in the treatment of pediatric inflammatory bowel disease.","volume":"70","author":"Newman","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"8","key":"2022111812243617400_CIT0016","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2013.10.019","article-title":"Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases.","volume":"12","author":"Kappelman","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2022111812243617400_CIT0017","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/MPG.0000000000000793","article-title":"Well-defined and reliable clinical outcome assessments for pediatric Crohn disease: a critical need for drug development.","volume":"60","author":"Sun","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"4","key":"2022111812243617400_CIT0018","doi-asserted-by":"crossref","first-page":"e1030","DOI":"10.1542\/peds.2011-1700","article-title":"Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease.","volume":"129","author":"Crandall","year":"2012","journal-title":"Pediatrics."},{"issue":"4","key":"2022111812243617400_CIT0019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/01.mpg.0000183350.46795.42","article-title":"Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience.","volume":"41","author":"Hyams","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"7","key":"2022111812243617400_CIT0020","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","article-title":"Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response.","volume":"138","author":"Turner","year":"2010","journal-title":"Gastroenterology."},{"issue":"1","key":"2022111812243617400_CIT0021","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data.","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics."},{"issue":"1","key":"2022111812243617400_CIT0022","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ibd.21452","article-title":"Short pediatric Crohn\u2019s disease activity index for quality improvement and observational research.","volume":"17","author":"Kappelman","year":"2011","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"2022111812243617400_CIT0023","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target.","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2022111812243617400_CIT0024","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cgh.2013.07.022","article-title":"Histologic remission: the ultimate therapeutic goal in ulcerative colitis?","volume":"12","author":"Peyrin-Biroulet","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2022111812243617400_CIT0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment.","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2022111812243617400_CIT0026","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ibd\/izz193","article-title":"Corticosteroid-free remission vs overall remission in clinical trials of moderate-severe ulcerative colitis and Crohn\u2019s disease.","volume":"26","author":"George","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2022111812243617400_CIT0027","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000003182","article-title":"Reduced systemic corticosteroid use among pediatric patients with inflammatory bowel disease in a large learning health system.","volume":"73","author":"Kandavel","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"6","key":"2022111812243617400_CIT0028","doi-asserted-by":"crossref","first-page":"e207378","DOI":"10.1001\/jamanetworkopen.2020.7378","article-title":"Association between steroid-sparing therapy and the risk of perianal fistulizing complications among young patients with Crohn disease.","volume":"3","author":"Adler","year":"2020","journal-title":"JAMA Network Open."},{"issue":"1","key":"2022111812243617400_CIT0029","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1542\/peds.2013-4103","article-title":"Effectiveness of anti-TNF\u03b1 for Crohn disease: research in a pediatric learning health system.","volume":"134","author":"Forrest","year":"2014","journal-title":"Pediatrics."},{"issue":"5","key":"2022111812243617400_CIT0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cgh.2020.04.060","article-title":"Factors associated with development of perianal fistulas in pediatric patients with Crohn\u2019s disease.","volume":"19","author":"Singer","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2022111812243617400_CIT0031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clinre.2019.05.008","article-title":"Effectiveness and safety of biologics in pediatric inflammatory bowel disease: real-life data from the Sicilian Network.","volume":"44","author":"Romeo","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"2","key":"2022111812243617400_CIT0032","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","article-title":"Management of paediatric ulcerative colitis, part 2: acute severe colitis\u2014an evidence-based consensus guideline from the European Crohn\u2019s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition.","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"5","key":"2022111812243617400_CIT0033","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ecco-jcc\/jjy206","article-title":"Management of paediatric patients with medically refractory Crohn\u2019s disease using ustekinumab: a multi-centred cohort study.","volume":"13","author":"Chavannes","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2022111812243617400_CIT0034","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children.","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology."},{"issue":"3","key":"2022111812243617400_CIT0035","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children.","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology."},{"issue":"13","key":"2022111812243617400_CIT0036","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otac009\/42952711\/otac009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/4\/2\/otac009\/47118632\/otac009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/4\/2\/otac009\/47118632\/otac009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:25:18Z","timestamp":1668774318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otac009\/6550531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otac009","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,18]]},"article-number":"otac009"}}